|
Cutting health cost helps new ideas sell |
|
April 21, 2010, St. Louis Post Dispatch
From St. Louis Post Dispatch:
Another local startup, C2N Diagnostics, is working with pharmaceutical companies to develop a test that can detect Alzheimer's at its earliest stages and also to guide effective treatment before patients manifest clinical symptoms. By the time symptoms are observed, neurological damage has occurred. So the goal is to catch Alzheimer's early — to delay or prevent symptoms in someone who has a high risk of developing it in the future.
"We need better measurements and tools to both discover drugs for Alzheimer's as well as to develop them clinically," said Joel Braunstein, a co-founder of C2N.
Cutting health care costs is just one of the messages pitched by medical entrepreneurs to investors.
Read more
|
|
|
C2N Diagnostics Announces Key New Hire and $1M+ Grant from Anonymous Donor to Support Alzheimer’s Biomarkers and Diagnostics Programs |
|
March 18, 2010
ST. LOUIS, MO – C2N Diagnostics announced today that it has received a multi-year grant from an anonymous donor. The award has the potential to exceed $1M in milestone-driven funding. It significantly accelerates C2N’s efforts to develop highly informative biomarkers implicated in Alzheimer’s disease and other central nervous system (CNS) disorders. |
|
Read more...
|
|
|
C2N Diagnostics Awarded "Fast Track" SBIR by NIA/NIH |
|
December 17, 2009
ST. LOUIS, MO – C2N Diagnostics has received a Fast Track Small Business Innovation Reasearch (SBIR) Award from the National Institute On Aging (NIA), part of the National Institutes of Health (NIH). The award of nearly $1 million will fund milestone-driven research to improve the diagnosis and treatment of Alzheimer’s disease. Dr. Tim West, C2N’s Director of Laboratory Operations, will serve as the study’s principal investigator.
|
|
Read more...
|
|
|
C2N Diagnostics Announces Successful Completion of Milestones Under $300,000 Alzheimer’s Drug Discovery Foundation Award |
|
November 12, 2009
ST. LOUIS, MO – C2N Diagnostics reported today that it has successfully accomplished each of the milestones defined under its partnership with the Alzheimer’s Drug Discovery Foundation (ADDF) and ADDF’s affiliate, the Institute for the Study of Aging. Under the terms of the collaborative financing, ADDF awarded $300,000 to C2N for the purpose of readying the company to perform an industry-grade SILK-Aß™ assay. |
|
Read more...
|
|
|
David Holtzman: Attacking Alzheimer's With a New Test for Amyloid Beta |
|
June 30, 2009, U.S. News and World Report
Neuroscientist David Holtzman was captivated by Alzheimer's disease as a medical student. Now the 47-year-old associate director of the Alzheimer's Disease Research Center at the Washington University School of Medicine in St. Louis, Holtzman says he realized that Alzheimer's "was going to be one of the biggest problems that we would face, and it was unsolved." Figuring out how the illness begins and how to prevent or slow it has been his goal ever since. |
|
Read more...
|
|
|
|
News and Information